Ovarian Cancer Research Grantees & Projects
Current Grantees
Our talented researchers come from top institutions around the world and are united in their passion to improve the lives – and outcomes – of patients with ovarian and related gynecologic cancers.
Collaborative Research Development Grant
Launched in 2004, this grant provides funds for research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. Support of $300,000 annually for three years, for a total of $900,000, will be awarded to the institution(s) where the recipients will conduct the research.
-
2024 Grant Recipients
Alberto Ciccia, PhD, Columbia University
Defining the impact of DNA repair variants on immune-based therapy of ovarian cancer at scale
Selvendiran Karuppaiyah, PhD, The Ohio State University
Identification of early molecular events and a novel biomarker for high grade serous ovarian cancer
Bethany Hannafon, PhD, University of Oklahoma Health Sciences Center
Development of a novel DCLK1-targeted CAR-T to prevent ovarian cancer metastatic recurrence2023 Grant RecipientsKristopher Sarosiek, PhD, Harvard T.H. Chan School of Public Health
Targeting Apoptotic Vulnerabilities in Ovarian CancerSimon Gayther, PhD, Cedars-Sinai Medical Center
iPSC Modeling of Ovarian Cancers in BRCA1 and 2 Mutation Carriers2022 Grant RecipientsJen-Tsan Chi, MD, PhD, Duke University
The Role of Ferroptosis in the Metastatic Ovarian CancerRonald Buckanovich, MD, PhD, Magee-Womens Research Institute
Role of Macrophage-secreted BIGH3 in Tumor ImmunityBenjamin Bitler, PhD, University of Colorado – Denver
A Machine Learning Approach to Chemotherapy-induced Remodeling of the Tumor2021 Grant RecipientsMartin Cannon, PhD, University of Arkansas for Medical Sciences
Understanding and Targeting Myeloid Populations in Ovarian CancerIvan Ahel, PhD, University of Oxford
Exploiting PARP-Modulating Enzymes in Ovarian Cancer Therapy2020 Grant RecipientsAndrew K. Godwin, PhD, University of Kansas Medical Center Research Institute
Tumor-Derived Extracellular Vesicle in Ovarian CancerSohrab Shah, PhD, Memorial Sloan Kettering Cancer Center
Profiling Co-Evolution of Ovarian Cancer and its Immune MicroenvironmentUgo Cavallaro, PhD, Fondazione Istituto Europeo di Oncologia e Centro
Cardiologico Fondazione Monzino
Interplay Between Ovarian Cancer Stem Cells and the Tumor MicroenvironmentSandra Orsulic, PhD, UCLA School of Medicine
Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma2019 Grant RecipientsRonald Buckanovich, MD, PhD, Magee-Womens Research Institute
Targeting Tumor Desmoplasia to Enhance ImmunotherapyRugang Zhang, PhD, The Wistar Institute
Developing Epigenetic Therapies for Ovarian Cancer2018 Grant RecipientsGordon Mills, MD, PhD, MD Anderson Cancer Center
Rational Combination Therapy in Ovarian CancerDavid Sabatini, MD, PhD, Whitehead Institute for Biomedical Research
A Personalized Approach to Identify and Target Ovarian Cancer Liabilities2017 Grant RecipientsTyler Curiel, MD, University of Texas Health Science Center at San Antonio
Rational Design of Effective Multi-modal Ovarian Cancer ImmunotherapyRonen Marmorstein, PhD, University of Pennsylvania
Chromatin Regulatory Mechanisms in Ovarian CancerKenneth Nephew, PhD, Indiana University
Epigenetic Vulnerabilities of Ovarian Cancer Stem CellsIe-Ming Shih, MD, PhD, Johns Hopkins University School of Medicine
Development of Targeted Therapies for Recurrent Ovarian Cancer2016 Grant RecipientsBeth Y. Karlan, MD, Cedars-Sinai Medical Center
Co-Evolution of Epithelial Ovarian Cancer and Tumor StromaDavid Spriggs, MD, Memorial Sloan Kettering Cancer Center
Novel Approaches to Immunotherapy2015 Grant RecipientsAnna Lokshin, PhD, University of Pittsburgh
Microenvironmental Control of Premalignant Lesions in Ovarian CancerAlexander Nikitin, MD, PhD, Cornell University
Cancer-prone Stem Cell Niches in Ovarian and Tubal EpitheliaMichael Yaffe, MD, PhD, Massachusetts Institute of Technology
Using Functional Genetics and Nanomedicine for Ovarian Cancer Treatments2014 Grant RecipientsTyler Curiel, MD, University of Texas Health Science Center at San Antonio
Rational Design of Effective Multi-modal Ovarian Cancer ImmunotherapyRonen Marmorstein, PhD, University of Pennsylvania
Chromatin Regulatory Mechanisms in Ovarian CancerUrsula Matulonis, MD, Dana Farber Cancer Institute
Rational Combinations of Novel Biologic Agents for Ovarian Cancer Therapy2013 Grant RecipientsSimon Gayther, PhD, University of Southern California
Functional Analysis of Genetic Susceptibility Loci to Identify Biomarkers and Candidate Genes Associated with Ovarian Cancer Initiation, Progression and OutcomeAnil K. Sood, MD, MD Anderson Cancer Center
Power of Platelets in Ovarian CancerElizabeth Swisher, MD, University of Washington
The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas2012 Grant RecipientsGeorge Coukos, M.D., Ph.D., University of Pennsylvania
Engineering Immune Cells to Better Recognize and Kill Ovarian CancerErnst Lengyel, MD, PhD, University of Chicago
Reprogramming of Ovarian Cancer Microenvironments by miRNAsMartin Matthew Matzuk, MD, PhD, Baylor College of Medicine
Diagnostic Strategies for Detection of Ovarian Cancer2011 Grant RecipientsKenneth Nephew, PhD, Indiana University
A New Approach to Treating Recurrent Ovarian Cancer and Newly Diagnosed DiseaseSanto Nicosia, MD, University South Florida
Ovarian Cancer: A Theme Based Approach Toward Identification of Novel Diagnostic and Therapeutic TargetsWeiping Zou, MD, PhD, University of Michigan – Ann Arbor
Understanding how Ovarian Cancer Stem Cells Play a Role in Disease Progression and Drug Resistance2009 Grant RecipientsAndrew Berchuck, MD, Duke University Medical Center
International Ovarian Cancer Association Consortium: Finding Genetic Markers of Ovarian Cancer Using PolymorphismsAndrew K. Godwin, PhD, Fox Chase Cancer Center
Understanding the Microenvironment Where Ovarian Cancer Grows as a Target for TreatmentAnil K. Sood, MD, MD Anderson Cancer Center
Novel Treatments for Ovarian Cancer Using siRNAs2008 Grant RecipientsGary Leiserowitz, MD, University of California – Davis
The Carbohydrate Components of Cellular Molecules: A New Way to Diagnose Ovarian Cancer?George Coukos, M.D., Ph.D., University of Pennsylvania
Engineering T Cells to Augment Natural Immunity to Ovarian CancerRobert C. Bast Jr., MD, MD Anderson Cancer Center
Autophagy and Ovarian Cancer2007 Grant RecipientsKunle Odunsi, MD, PhD, Roswell Park Cancer Institute
Enhancing Immunity to Ovarian Cancer TumorsMartin Matthew Matzuk, MD, PhD, Baylor College of Medicine
MicroRNA’s as Diagnostic and Therapeutic Targets in Ovarian CancerJonathan S. Berek, MD, MMS, Stanford University
Leading the Effort to Develop Vaccines and Immunotherapy for Ovarian Cancer2006 Grant Recipients
Bo Rueda, PhD, Massachusetts General Hospital
Understanding the Key Molecular Pathways that Drive Ovarian CancerPeter Laird, PhD, University of Southern California/Keck Medical School
Molecular Changes to DNA that Contribute to Ovarian CancerRonny I. Drapkin, MD, PhD, Dana Farber Cancer Institute
Ovarian Cancer Biomarkers: Identification, Validation and Assessment of Biological Function2005 Grant Recipients
Anil K. Sood, MD, MD Anderson Cancer Center
Novel siRNA Based Therapeutic Approaches for Ovarian Carcinoma
Andrew K. Godwin, PhD, Fox Chase Cancer Center
Therapeutic Targeting of the Tumor Microenvironment in Ovarian CancerAndrew Berchuck, MD, Duke University Medical Center
International Ovarian Cancer Association Consortium2004 Grant RecipientsCarol Aghajanian, MD, PhD, Memorial Sloan Kettering Cancer Center
Novel Approaches to Ovarian Cancer Treatment
Collaborative Research Development Grant – Microsoft AI for Health
Launched in 2022, this grant is the result of a unique partnership between OCRA and Microsoft AI for Health, a philanthropic program at Microsoft. This collaboration will help OCRA accelerate ovarian cancer research by harnessing the power of data science and Artificial Intelligence (AI), potentially leading to new insights into the disease. The grant will provide funds for ovarian cancer and/or related gynecologic cancers research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Support of $300,000 annually for three years, for a total of $900,000, will be awarded to the institution(s) where the recipients will conduct the research in addition to in-kind support from Microsoft.
-
2024 Grant Recipients
Rugang Zhang, PhD, MD Anderson Cancer Center
AI-guided single-cell transfer learning model to predict precision medicine in ovarian cancer2023 Grant RecipientsDaniel Heller, PhD, Memorial Sloan Kettering Cancer Center
Perception-Based Detection of an Ovarian Cancer Disease Fingerprint
Shayan Shams, PhD, San Jose State University
Employing AI to Predict Clinical Outcomes in Ovarian Cancer2022 Grant RecipientsSohrab Shah, PhD, Memorial Sloan Kettering Cancer Center
Inferring Mutational Processes and Patient Stratification From Standard-of-Care Clinical Imaging
Early Career Investigator Grant
The Early Career Investigator Grant (formerly the Liz Tilberis Early Career Award) is for junior faculty (Assistant Professor level) with a strong commitment to an investigative career in ovarian cancer or related gynecologic cancer research. Each grantee will receive a three-year grant of $150,000 per year, for a total of $450,000.
-
2024 Grant Recipients
Nicole James, PhD, Women & Infants Hospital of Rhode Island
The evaluation of amphiregulin as a novel immunomodulatory high grade serous ovarian cancer therapy
Laura Chambers, DO, The Ohio State University
The Impact of Gut Microbiome and Probiotics on Chemotherapy Response in Ovarian Cancer Patients
Sridevi Challa, PhD, The University of Chicago
Targeting Ribosomal Function to Overcome Chemoresistance in Ovarian Cancer
Nicole Marjon, MD, PhD, University of Colorado – Denver
Reprograming the Ovarian Cancer Immune Microenvironment Via Inhibition of MDSC Recruitment
Sarah Gitto, PhD, University of Pennsylvania
PARP-targeted PET imaging to measure response to PARP inhibitor and immunotherapy in ovarian cancer
Melica Brodeur, MD, Jewish General Hospital
Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer
Joshua Doloff, PhD, Johns Hopkins University
Crystallized drug, biomaterial delivery system for treating ovarian cancerCharles Ishak, PhD, MD Anderson Cancer Center
Repetitive elements as a therapeutic opportunity to intercept ovarian high grade serous carcinoma2023 Grant RecipientsXiaowen Hu, PhD, University of Pennsylvania
Targeting Chromatin Modifiers to Treat Ovarian CancerBrooke Howitt, MD, Stanford University
Identifying the Cell of Origin for High- Grade Serous CarcinomaPriyanka Verma, PhD, Washington University in St. Louis
Role of Chromatin on PARP Inhibitor Responses in BRCA-Mutant Ovarian CancerKyle Payne, PhD, Rutgers University
Mitochondrial Stress Impairs Protective T Cell Immunity in Ovarian CancerHaider Mahdi, MD, Magee-Womens Research Institute
Targeting CD47-SIRPa Axis to Overcome Therapy Resistance in Ovarian CancerBob McGray, PhD, Roswell Park Cancer Institute
BiTE-secreting T cells for Adoptive T cell Therapy in Ovarian CancerRichard Adeyemi, DVM, PhD, Fred Hutchinson Cancer Research Center
Synthetic Lethality of the Protexin and BRCA Complexes in Ovarian Cancer2022 Grant RecipientsLivnat Jerby, Stanford University
Targeting multifactorial immune evasion mechanisms in ovarian cancerHaineng Xu, PhD, University of Pennsylvania
Strategies to Exploit Genetic Alterations in Clear-Cell Ovarian CancerJasmine Plummer, PhD, Cedars-Sinai Medical Center
Chemopreventative Targets in BRCA1 Carrier Models with P53 Lesions (Gail Baird Foundation Research Grant Recipient)Lindsay Brubaker, MD, University of Colorado – Denver
Targeting Chromobox 2 to Overcome Macrophage-induced Immune SuppressionSammy Ferri-Borgogno, PhD, MD Anderson Cancer Center
BRCA-deficient Ovarian Cancer and IFITM3: a New Power CoupleMaria Victoria Botuyan, PhD, Mayo Clinic Rochester
Probing How RAD18 and BARD1 Antagonize 53BP1 in HR DNA RepairChi Lam Au Yeung, PhD, MD Anderson Cancer Center
Cancer-derived Exosomal miRNAs Modulate Ovarian Tumor Microenvironment2021 Grant RecipientsIchiko Kinjyo, MD, PhD, University of New Mexico
A Novel Mechanism for the Immunomodulatory Effects of PARP-inhibitorArun Kanakkanthara, PhD, Mayo Clinic
Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian CancerLiya Ding, PhD, Dana Farber Cancer Institute
Targeting Therapeutic Resistance to PARP Inhibition in Ovarian CancerSandra Cascio, PhD, Magee-Womens Research Institute
EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC2020 Grant RecipientsNidhi Sahni, PhD, MD Anderson Cancer Center
Systems Approach for PARP-based Novel Combination Therapy in Ovarian CancerJames Duncan, PhD, Fox Chase Cancer Center
Exploring PROTAC-Mediated Degradation of BRD4 in Ovarian CancerMark Eckert, PhD, University of Chicago
The Fate and Function of Adipocytes in Ovarian Cancer MetastasisSudipto Ganguly, PhD, Johns Hopkins University
Characterizing a Novel Checkpoint Axis in High-Grade Serous Ovarian CancerBrooke Howitt, MD, Stanford University
Identifying the Cell of Origin for Ovarian High-Grade Serous CarcinomaSunila Pradeep, PhD, Medical College of Wisconsin
Epigenetic Causes of Acquired Resistance of Anti-VEGF TherapyBoris Winterhoff, MD, University of Minnesota Twin Cities
Precision Medicine in Ovarian Cancer: Using Single Cell AnalysisDmitriy Zamarin, MD, PhD, Memorial Sloan Kettering Cancer Center
Chromatin Remodeling and Immunotherapy in Ovarian Cancer2019 Grant RecipientsMin Soon Cho, PhD, MD Anderson Cancer Center
The Role of Platelet in the Regulation of Immune Response to Ovarian CancerZihua Gong, MD, PhD, Cleveland Clinic
DNA Repair Pathways as Targets for Therapy-Resistant Ovarian CancerXiaowen Hu, PhD, University of Pennsylvania
Targeting Chromatin Remodeling Complex to Treat Ovarian CancerKate Lawrenson, PhD, Cedars-Sinai Medical Center
Elucidating the Role of SOX17 in HGSOCElizabeth Stover, MD, PhD, Dana Farber Cancer Institute
Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian CancerTakemasa Tsuji, PhD, Roswell Park Comprehensive Cancer Center
Utilization of Tumor-recognizing CD4+T Cells in Cancer ImmunotherapyKris Wood, PhD, Duke University
Precision Targeting of Altered Mitochondrial States in Ovarian Cancer2018 Grant RecipientsMaria Victoria Botuyan, PhD, Mayo Clinic
Probing the Antagonistic Roles of 53BP1 and RAD18 in HR DNA RepairKatherine Fuh, MD, PhD, Washington University in St. Louis
Inhibition of Metastasis in BRCA2-associated Ovarian CancersHilary Kenny, PhD, The University of Chicago
The Role of Mesothelial Cells in Ovarian Cancer MetastasisChunsheng Li, PhD, University of Pennsylvania
Imaging Guided Immunotherapy Targeting CD248 for Epithelial Ovarian CancerSumegha Mitra, PhD, Indiana University
UCHL1 Regulates Oncogenic Signaling in Ovarian CancerJian Yuan, PhD, Mayo Clinic
The Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer2017 Grant RecipientsAlessia Baccarini, PhD, Mount Sinai School of Medicine
Regulation of the Immune Checkpoint PD-L1 in Ovarian CancerRonald Chandler, PhD, Michigan State University
Integrated Roles of Epigenetics and Cell Signaling in Ovarian CancerIlana Chefetz, PhD, University of Michigan
Drugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian CancerMichael Goldberg, PhD, Dana Farber Cancer Institute
Rational Immunity to Improve Survival Following Standard-of-care ChemoSunila Pradeep, PhD, Medical College of Wisconsin
Epigenetic Causes of Acquired Resistance to Anti-VEGF TherapyBoris Winterhoff, MD, University of Minnesota Twin Cities
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis2016 Grant RecipientsPradeep Chaluvally-Raghavan, PhD, Medical College of Wisconsin
Unexpected Role of CLDN11 cdRNA in Ovarian CancerAlberto Ciccia, PhD, Columbia University Medical Center
Defining the Molecular Mechanisms of BRCA1-dependent Tumor SuppressionZihua Gong, MD, PhD, MD Anderson Cancer Center
DNA Repair Pathways as Target for Therapy-Resistant Ovarian CancerHui Shen, PhD, Van Andel Research Institute
An Epigenomic Approach to Delineate Cells of Origin in Early TumorigenesisAlexandra Snyder Charen, MD, Memorial Sloan Kettering Cancer Center
Unmasking Ovarian Cancers to Induce Immune ControlSherry Wu, PhD, MD Anderson Cancer Center
Re-activating Anti-tumor Immunity Using Non-coding RNAs2015 Grant RecipientsSarah Adams, MD, University of New Mexico
A Combination Therapy for Hereditary Ovarian CancerCesar Castro, MD, Massachusetts General Hospital
Leveraging DNA-Barcoding for Integrated Profiling of Ovarian CancerDaniela Dinulescu, PhD, Brigham and Women’s Hospital
Modeling Serous Ovarian Carcinoma Using Genetic Markers Specific for the Distal Fallopian TubeYutaka Shoji, PhD, Michigan State University
ARID1A Regulates ATAD2 in Ovarian CancerTakemasa Tsuji, PhD, Roswell Park Cancer Institute
Utilization of Tumor-recognizing CD4+T cells in Cancer ImmunotherapySarah Walker, PhD, Dana Farber Cancer Institute
Targeting Transcription Factor Networks for Ovarian Cancer TherapyKris Wood, PhD, Duke University
Defining New Combination Therapies for High-grade Serous Ovarian Cancer2014 Grant RecipientsHiu Wing (Tony) Cheung, PhD, Medical University of South Carolina
Functional Genomics Approaches to Identify Ovarian Cancer GenesRachel Grisham, MD, Memorial Sloan Kettering Cancer Center
Determining the Molecular Drivers of Low-Grade Serous Ovarian CancerRyan B. Jensen, PhD, Yale University
A Cellular Switch to Modulate BRCA2-mediated Tumor ProgressionSelvendiran Karuppaiyah, PhD, Ohio State University
New Type of Experimental Drug for Ovarian CancerBarbara Stulken Norquist, MD, University of Washington
Molecular Biomarkers to Predict PARP Inhibitor Response in Ovarian CancerMatthias Stephan, MD, PhD, Fred Hutchinson Cancer Research Center
In vivo Programming of Ovarian Tumor-reactive T-cells Using NanoparticlesS John Weroha, MD, PhD, Mayo Clinic
Ovarian Cancer Surrogates to Study Platinum Resistance2013 Grant RecipientsMaria Barbolina, PhD, University of Illinois – Chicago
Chemokine-Dependent Control of Survival in Ovarian CarcinomaStephanie Gaillard, MD, PhD, Duke Cancer Institute
Evaluating ERRalpha as a Novel Therapeutic Target in Ovarian CancerMichael Goldberg, PhD, Dana Farber Cancer Institute
siRNA Targeting Immunosuppressive and Oncogenic Pathways in Ovarian CancerXin Huang, PhD, Magee-Womens Research Institute
Noval Strategy of Metabolic Targeting Ovarian Cancer: Focusing on the Tumor Hypoxia PathwayMythreye Karthikeyan, PhD, University of South Carolina
Investigating the TGFß Superfamily as Therapeutic Targets in Ovarian CancerJoyce Liu, MD, MPH, Dana Farber Cancer Institute
Investigating ErbB3 as a Novel Therapeutic Target in Ovarian Cancer2012 Grant RecipientsKaren Cowden Dahl, PhD, Indiana University
Investigation of ARID3B Splicing as a Novel Therapeutic Target for Ovarian CancerDaniela Dinulescu, PhD, Brigham and Women’s Hospital
Modeling Serous Ovarian Carcinoma Using Genetic Markers Specific for the Distal Fallopian TubeIvan Garcia-Bassets, PhD, University of California – San Diego
Targeting the Epigenetic Plasticity of the Platinum Response in Drug-resistant Ovarian Cancer CellsShannon Hawkins, MD, PhD, Baylor College of Medicine
The Function of ARID1A in the Transformation of Endometriosis to Ovarian CancerW. Ruprecht Wiedemeyer, PhD, Cedars-Sinai Medical Center
Ovarian Cancer Evolution After Targeted Therapy2011 Grant RecipientsSarah Adams, MD, University of Pennsylvania
Development of Combination Therapy with PARP-Inhibitors and Immunomodulation for BRCA1-Epithelial Ovarian CancerJoanna Burdette, PhD, University of Illinois – Chicago
Identifying Early Events in Ovarian cancer Using a 3-D Model of Ovarian TissuesAnalisa DiFeo, PhD, moun, Mount Sinai School of Medicine and Case Western Reserve University
What is the Relationship Between an miRNA Molecule and Resistance to Chemotherapy?Selvendiran Karuppaiyah, PhD, Ohio State University
Safe, Targeted, Antitumor Therapeutics (STAT3 Inhibitors) for Ovarian CancerAnn Klopp, MD, PhD, MD Anderson Cancer Center
Fat Cells May Be Source of Stem Cells That Promote Ovarian CancerBin Zhang, MD, PhD, University of Texas Health Science Center at San Antonio
Developing Ways to Enhance the Immune System’s Ability to Fight Ovarian CancerMary Zhang, MS, PhD, University South Florida
Understanding Mechanisms that Lead to Resistance to Platinum-based Treatments2009 Grant RecipientsKathryn Terry, ScD, Brigham and Women’s Hospital
The Role of Genetics and Environment on Telomere Length in Ovarian CancerLin Zhang, MD, University of Pennsylvania
MicroRNAs, PI-3 kinase, and Ovarian Cancer Stem Cell Differentiation2008 Grant RecipientsAnika Agarwal, MD, MPhil, Tufts Medical Center
Characterizing a Key Biological Pathway in the Ovarian Cancer MicroenvironmentRonald Buckanovich, MD, PhD, University of Pennsylvania
Tumor Blood Vessels in Ovarian Cancer Development, Diagnosis and for TreatmentJose Conejo-Garcia, MD, PhD, The Wistar Institute
Reprogramming Immune Cells to Treat Ovarian CancerErnst Lengyel, MD, PhD, University of Chicago
Understanding the Molecular Biology of Metastasis in Ovarian CancerMonique Spillman, MD, PhD, University of Colorado – Denver
Determining the Role of Estrogen in Ovarian CancerRugang Zhang, PhD, Fox Chase Cancer Center
Exploiting Natural Cell Behavior to Stop Cancer Cell Growth2007 Grant RecipientsDeborah Altomare, PhD, University of Central Florida
Clarifying the Molecules Involves in Ovarian Cancer Growth and ProgressionStephen L. Rose, MD, University of Wisconsin-Madison Medical School
Studying the Molecules Involved in Ovarian Cancer Development2006 Grant RecipientsLin Zhang, MD, University of Pennsylvania
The Role of PIK3CA in Epithelial Ovarian CancerKathryn Terry, ScD, Brigham and Women’s Hospital
Telomeres and Telomerase in Relation to Ovarian Cancer RiskDouglas A. Levine, MD, Memorial Sloan Kettering Cancer Center
Method to Determine if a Male Hormone, Naturally Present in Woman, Affects the Risk of Developing Ovarian CancerHeidi Gray, MD, University of Washington
Using Antibodies to Detect Early Ovarian CancerDenise C. Connolly, PhD, Fox Chase Cancer Center
Developing Mouse Models of Ovarian Cancer2005 Grant RecipientsAndrew Li, MD, Cedars-Sinai Medical Center
Testing Medications for Other Conditions to Treat Ovarian CancerJose Conejo-Garcia, MD, PhD, Dartmouth Medical School
Vascular Leukocytes as novel anti-tumor therapeutic targetsJeremy Chien, PhD, Mayo Clinic
How Cell Shape Changes Lead to Metastasis in Ovarian Cancer2004 Grant RecipientsErnst Lengyel, MD, PhD, University of Chicago
Role and Regulation of Hepatocyte Growth Factor and c-Met in Ovarian CancerOliver Dorigo, MD, PhD, University of California – Los Angeles
Phenotypic and Molecular Effects if Phosphoinositide 3-Kinase (PI3 Kinase)/Akt Pathway Activation in Mouse Ovary Using Conditional Deletion of Tumor Suppressor Gene PTENRonald Buckanovich, MD, PhD, University of Michigan
Identification and Validation of Clinically Relevant Targets in Ovarian Tumore Vasculature2003 Grant RecipientsLin Zhang, MD, University of Pennsylvania
Transgenic Approaches to Study Ovarian Cancer PreventionSusan K. Murphy, PhD, Duke University Medical Center
How Chemical Alterations to the DNA-but not its Sequence-May Play a Role in Ovarian CancerDouglas A. Levine, MD, Memorial Sloan Kettering Cancer Center
Novel Approaches to the Androgen Pathway and Genetic Predisposition to Ovarian CancerDenise C. Connolly, PhD, Mayo Clinic
How Cell Shape Changes Lea to Metastasis in Ovarian Cancer2002 Grant RecipientsJonathan Lancaster, MD, Moffitt Cancer Center and Research Institute
Defining Genetic Pathways that Underlie Ovarian Carcinogenesis Using Microarray Expressoin AnalysisDavid E. Cohn, MD, Ohio State University
Targeting Tumor Blood Vessel Growth Factors with Antibodies as a New Ovarian Cancer Treatment2001 Grant RecipientsRebecca Liu, MD, University of Michigan
Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Pathogenesis, Prognosis, and ChemoresistanceKimberly Kalli, PhD, Mayo Clinic
Functional Significance of Insulin Receptors in Epithelial Ovarian Cancer: Therapeutic ImplicationsChristina Bandera, MD, Dana Farber Cancer Institute
The Molecular Basis of Recurrent Ovarian Cancer and Primary Peritoneal Cancer2000 Grant RecipientsKaren H. Lu, MD, MD Anderson Cancer Center
Understanding the Molecular Differences in Histologic Grades of Ovarian Cancer: Implications for Discovering New Prognostic MarkersChristos Patriotis, PhD, Fox Chase Cancer Center
Molecular Genetic Mechanisms of Ovarian OncogenesisRobin Farias-Eisner, MD, PhD, UCLA School of Medicine
O-glycosylation: a Molecular Mechanism for Transciptional Regulation, Cellular Transformation and Nitric Oxide (NO) Mediated Tumoricidal Activity
Mentored Investigator Grant
The Mentored Investigator Grant (formerly the Ann and Sol Schreiber Mentored Investigator Award) provides funding for trainees (post-doctoral fellows or clinical fellows) working under the supervision of a mentor who is a recognized leader in ovarian cancer research. Applicants must have an MD or a PhD degree. The grant provides a total of $100,000 to be used over one or two years and will encourage the recipient’s research career in the field of ovarian cancer and related gynecologic cancers.
-
2024 Grant Recipients
Martins Ayoola-Adeola, MD, University of California – Los Angeles
Perioperative Nanotherapy for Ovarian CancerWhitney Grither, MD, PhD, Washington University in St. Louis
Examining the role of cancer-associated mesothelial cells in ovarian cancer metastasisMona Singh, PhD, Medical College of Wisconsin
Unexplored role of specific subpopulation B cells in the ovarian cancer microenvironmentNicole Gull, PhD, Cedars-Sinai Medical Center
Charting inflammasome-driven immune infiltration in homologous recombination deficient HGSOCMacLean Sellars, MD, Dana Farber Cancer Institute
Expanding the Antigen Landscape in High Grade Serous Ovarian Cancer2023 Grant RecipientsChae Young Han, PhD, MD Anderson Cancer Center
Detection of CA125-Negative Persistent and Recurrent Ovarian CancerApoorva Uboveja, PhD, University of Pittsburgh
A Metabolic-Epigenetic Switch Affects DNA Repair Pathway ChoiceSonam Mittal, PhD, Medical College of Wisconsin
Exosome Loaded eIF4A1 Dependent Translational Reprogramming in MacrophagesAntonio Delgado-Gonzalez, PhD, Stanford University
Mapping the Spatial Proteomic Landscape of Ovarian TumorsJoshua Eggold, PhD, University of Pennsylvania
Functional Characterization of Distinct Ovarian Cancer Macrophage SubsetsBisiayo Fashemi, PhD, Washington University in St. Louis
Organoids to Evaluate an Epigenetic Drug Regimen for HR Proficient OvarianChen Wang, PhD, MD Anderson Cancer Center
Epigenetically Targeting Ovarian Cancer Associated Mesenchymal Stem CellsAndres Valdivia, PhD, Northwestern University
Complement Activation at the Interface Between Cancer Cells and AdipocytesDuaa Al-Rawi, MD, PhD, Memorial Sloan Kettering Cancer Center
Examining the Early Events in Fallopian Tube Transformation2022 Grant RecipientsThales Nepomuceno, PhD, Moffitt Cancer Center and Research Institute
Tackling PARPi sensitivity in HRP and HRD cellsZelei Yang, PhD, Dana Farber Cancer Institute
Re-engaging the Anti-tumor Immune Response Against Ovarian CancerImade Williams, PhD, Indiana University
Targeting MYC-HSF1 co-Amplification in High Grade Serous Ovarian CancerErin Wesley, PhD, University of Minnesota Twin Cities
Impact of Cytomegalovirus and Inflammation on NK Cells in Ovarian CancerAmrita Salvi, PhD, The University of Illinois at Chicago
Investigating the mechanism of action of PHY34 in HGSOCPamela Rojas de Santiago, PhD, University of Pennsylvania
Investigating the Therapeutic Potential of CRABP2 in HGSOCVeethika Pandey, PhD, University of Pennsylvania
Overcoming T Cell Exhaustion in Ovarian Cancer Tumor MicroenvironmentBenjamin Johnson, PhD, Van Andel Research Institute
Ovarian Cancer Stem-like Cell Differentiation Trajectories in Single CellsPatrick Innamarato, PhD, Moffitt Cancer Center and Research Institute
Determination of the Immunogenic Antigen Repertoire in Ovarian CancerMelica Brodeur, MD, Memorial Sloan Kettering Cancer Center
Exploiting SMARCA4 Alterations for New Therapeutics in Ovarian CancersGamze Bildik Elcik, PhD, MD Anderson Cancer Center
DIRAS3 Inhibits KRAS and Sensitizes LGSOC Cells to Anti-autophagic Therapy2021 Grant RecipientsAnup Singh, PhD, La Jolla Institute for Immunology
Studying the Role of BRCA1 in Regulating Heterochromatin Structure and Function in Ovarian CancerMelanie Weigert, PhD, University of Chicago
Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNAAnne M. van Harten, PhD, Thomas Jefferson University
Targeted MDM2 Degradation as a Novel Treatment for Ovarian CancerBojana Stefanovska, PhD, University of Minnesota Twin Cities
APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOCSammy Ferri-Borgogno, PhD, MD Anderson Cancer Center
Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian CancerSridevi Challa, PhD, UT Southwestern Medical Center
Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality ControlBenoît Bragantini, PhD, Mayo Clinic
Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EMRonja Anugwom, PhD, MD Anderson Cancer Center
Determine Resistance Mechanisms to ATR Inhibition in Ovarian CancersWei Zhou, PhD, The Wistar Institute
Targeting the mevalonate pathway in ARID1A-mutated ovarian cancerXueyang Yu, PhD, Massachusetts Institute of Technology
Macrophage Control of the Microenvironment Drives HGSOC Progression2020 Grant RecipientsDavid Chapel, MD, Brigham and Women’s Hospital
The Migratory Precursor and Serous CarcinogenesisYilun Deng, PhD, University of Texas Health Science Center at San Antonio
CD122-Selective IL-2 Complexes as Novel Ovarian Cancer TherapyElizabeth Lee, MD, Dana Farber Cancer Institute
Phase II Trial of Gemcitabine+ATR Inhibitor: Translational StudiesJianhuang Lin, PhD, The Wistar Institute
Targeting ER Stress Pathway in CARM1-Expressing Ovarian CancerDuygu Ozmadenci, PhD, University of California – San Diego
Sensitizing Ovarian Cancer to ImmunotherapiesElizabeth Raupach, PhD, The Translational Genomics Research Institute
Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHTCamilla Salvagno, PhD, Weill Medical College of Cornell University
Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-EnvironmentsJanice Santiago, PhD, MD Anderson Cancer Center
Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian CancerIgnacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center
Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian CancerMorozov Yaroslav, PhD, University of Pennsylvania
The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells2019 Grant RecipientsKristin G. Anderson, PhD, Fred Hutchinson Cancer Research Center
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian CancerAlexander Cole, PhD, Magee-Womens Research Institute
Investigating Regulators of Quiescence in Epithelial Ovarian CancerSarah Gitto, PhD, University of Pennsylvania
Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian CancerGuy Katz, MD, PhD, MD Anderson Cancer Center
Therapeutic miRNA Targeting for Ovarian CancerIsaac Klein, MD, PhD, Dana Farber Cancer Institute
Transcriptional Regulatory Landscape of High Grade Serous Ovarian CancerJohn Krais, PhD, Fox Chase Cancer Center
Examining the Role of RNF168 in BRCA1 Mutant Ovarian CancerMarilyne Labrie, PhD, Oregon Health and Science University
Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian CancerJing Li, MD, PhD, University of Michigan
ARID1A Drives Ovarian Cancer ImmunotherapyShariska Petersen, MD, University of Kansas Medical Center Research Institute
Cyclin E and BRD4 as Markers for a New PARPi Drug CombinationAlba Rodriguez-Garcia, PhD, University of Pennsylvania
Targeting MISIIR with CAR T Cells for the Treatment of Ovarian CancerElaine Stur, PhD, MD Anderson Cancer Center
Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian CancerShuai Wu, PhD, The Wistar Institute
Synthetic Lethality for ARID1A Mutation in Ovarian CancerHaineng Xu, PhD, University of Pennsylvania
A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian CancersZvi Yaari, PhD, Memorial Sloan Kettering Cancer Center
Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer2018 Grant RecipientsDamayanti Chakraborty, PhD, Massachusetts General Hospital
Understanding Epigenetic Regulation of Copy Number Gains in Ovarian CancerDaniele Chaves-Moreira, PhD, University of Pennsylvania
Isolation and Characterization of the PAX8 Transcriptional ComplexChin-Chi Chen, PhD, Johns Hopkins University
Determining the Role of ARID1A in 53BP1-mediated DNA Damage RepairShih-Hsun Chen, PhD, Beckman Research Institute of the City of Hope
Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer TherapyMatthew Dean, PhD, University of Illinois – Chicago
The Ovarian Microenvironment in Metastasis of Fallopian Tube Derived CancerMarcela Haro, PhD, Cedars-Sinai Medical Center
Cancer Associated Fibroblasts Hinder the B Cell Anti-Tumor ResponseYe Hu, MD, PhD, Cedars-Sinai Medical Center
Reciprocal Roles of CAFs and CD4+ T Cells in Cancer ProgressionJustyna Kanska, PhD, Cedars-Sinai Medical Center
Identifying Synthetic Lethal Targets to Mutant p53 in Development of HGSOCGoldie Lui, PhD, Fred Hutchinson Cancer Research Center
Identifying Novel Targeted Therapies for MYC-driven Ovarian CancerSarah Stuckelberger, MD, University of Pennsylvania
Development of A Novel Syngeneic Model System for Ovarian Cancer ResearchYinu Wang, PhD, Northwestern University
Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem CellsShuang Zhang, PhD, New York University School of Medicine
Modeling Human HGSOC Using Fallopian Tube Organoid Cultures2017 Grant RecipientsNabanita Chatterjee, PhD, MD Anderson Cancer Center
Ovarian Cancer Disrupts Circadian Cortisol RhythmsMarion Curtis, PhD, University of Chicago
Mediators of Chemosensitivity and Immunotherapy TargetsAnniina Farkkila, MD, PhD, Dana Farber Cancer Institute
Overcoming PARP Inhibitor Resistance in Ovarian CancerJagmohan Hooda, PhD, University of Pennsylvania
Loss of H2Bub1 Rewires Glutamine Metabolism During Progression of HGSOCGilbert Huang, PhD, MD Anderson Cancer Center
Targeting Dormant Ovarian Cancer Cells with Peptide Inhibitors of AutophagyDongyu Jia, PhD, Cedars-Sinai Medical Center
COL11A Is A Highly Specific Therapeutic Target in Cancer-Activated StromaVenkatesh Krishnan, PhD, Stanford University
Omental Macrophages: Drivers of Ovarian Cancer MetastasisXianzhi Lin, PhD, Cedars-Sinai Medical Center
Systematic Discovery of LncRNA Interactome in Epithelial Ovarian CancerBeatrice Rondinelli, PhD, Dana Farber Cancer Institute
EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian TumorsPriyanka Verma, PhD, University of Pennsylvania
BRCA-Independent DNA Repair Pathways in Ovarian Cancer2016 Grant RecipientsJessica Chacon, PhD, University of Pennsylvania
Investigating the Role of Immunosuppressive Molecules in Ovarian CancerSong Yi Ko, PhD, MD Anderson Cancer Center
A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF TherapyJill Madden, PhD, Inc., University of Kansas Medical Center Research Institute
The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and SensitivityAbir Mukherjee, PhD, University of Chicago
Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian CancerDebarshi Roy, PhD, Mayo Clinic
Crosstalk Between Glycolytic Pathway Inhibition and Increased AutophagyQian Tan, MD, PhD, Stanford University
Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian CancersRyan Williams, PhD, Memorial Sloan Kettering Cancer Center
An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease DetectionNur Yucer, PhD, Cedars-Sinai Medical Center
Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCsFan Zhao, PhD, Stanford University
Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA LibraryHengrui Zhu, PhD, The Wistar Institute
Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer2015 Grant RecipientsJuan Cubillos-Ruiz, PhD, Weill Medical College of Cornell University
ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer ImmunityJustyna Filant, PhD, MD Anderson Cancer Center
Novel Extra Cellular RNA-based Combinatorial RNA Inhibition TherapyXiaowen Hu, PhD, University of Pennsylvania
Long Non-coding RNAs in Epithelia Ovarian CancerPetar Jelinic, PhD, Memorial Sloan Kettering Cancer Center
EMSY Suppresses HDR in a BRCA2-interaction-independent MannerZeina Kais, PhD, Dana Farber Cancer Institute
Synthetic Lethality Between CCNE1 Amplification and USP1 InhibitionBob McGray, PhD, Roswell Park Cancer Institute
Combination Oncolytic Virotherapy/ACT for Ovarian Cancer TreatmentAlfredo Perales-Puchalt, MD, The Wistar Institute
Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian CancerNicole Spardy, PhD, Dana Farber Cancer Institute
Identification of New Genetic Dependencies in HR-deficient Ovarian CancersWei Wei, PhD, Massachusetts General Hospital
Genomic Analysis to Predict Recurrence in Early Stage Ovarian CancerOladapo Yeku, MD, PhD, Memorial Sloan Kettering Cancer Center
A Phase I Trial Using Chimeric Antigen Receptors in Ovarian Cancer Patients2014 Grant RecipientsNima Aghaeepour, PhD, Stanford University
Computationally-guided Characterization of Therapy-resistant Ovarian TumorsRaphael Ceccaldi, PharmD, PhD, Dana Farber Cancer Institute
A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian CancersIlana Chefetz, PhD, University of Michigan
A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic TargetingEllen Cheon, PhD, Cedars-Sinai Medical Center
Collagen-Remodeling Genes Provide a Niche for Ovarian CancerLaura Dillon, PhD, University of Virginia
Differential MicroDNA Generation in Ovarian CancerMo Li, PhD, University of Michigan
Mechanism of PARP Inhibitor in Ovarian Cancer Therapy CancerKyung Hee Noh, PhD, MD Anderson Cancer Center
Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian CancerShailja Pathania, PhD, Dana Farber Cancer Institute
Novel Therapeutic Targets for High-Grade Serous Ovarian CarcinomaMegan Rice, ScD, Brigham and Women’s Hospital
Dietary Fat, Cholesterol, and Ovarian Cancer RiskYang Yang, PhD, Yale University
P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-ResistanceChi Lam Au Yeung, PhD, MD Anderson Cancer Center
Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer ProgressionYuyu Yuyu, PhD, Johns Hopkins University School of Medicine
Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer2013 Grant RecipientsPradeep Chaluvally-Raghavan, PhD, MD Anderson Cancer Center
Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and TherapyRonald Chandler, PhD, University of North Carolina – Chapel Hill
A Genetically Relevant Mutant Mouse Model of Epithelial Ovarian CancerDiana Hargreaves, PhD, Stanford University
Targeting Ovarian Cancer via Cooperative Oncogene InteractionsChristine Lawson, PhD, University of California – San Diego
Testing the FAK and Talin Signaling Linkage in Ovarian Tumor Cell MetastasisTeng Ma, MD, PhD, University of Michigan – Ann Arbor
The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian CancerDavid Pepin, PhD, Massachusetts General Hospital
Mechanisms and Markers to Target a Stem Enriched Population of Primary Ovarian
Cancer Ascites with the Müllerian Inhibiting SubstanceYin Wang, PhD, Mayo Clinic Jacksonville
Protein Kinase C iota is a Novel Therapeutic Target for Ovarian Cancer Treatment2012 Grant RecipientsBin Guan, PhD, Johns Hopkins University School of Medicine
Functional Characterization of the Tumor Suppressor ARID1A in Ovarian CancerKate Lawrenson, PhD, University of Southern California
Modeling Stem Cell Origins of Epithelial Ovarian CarcinomasHanqing Liu, PhD, Fox Chase Cancer Center
Targeting Signaling Networks via RNAi to Improve Therapy for Ovarian CancerNgai Na Co, PhD, MD Anderson Cancer Center
The Role of Stromal microRNA 21 in Omental Ovarian Cancer ProgressionSee-Hyoung Park, PhD, Stanford University
Targeting Ovarian Cancer with Combination of Olaparib and BepridilMelinda Yates, PhD, MD Anderson Cancer Center
Unraveling the Initiation of Ovarian Cancer: The BRCA1-Heterozygous Mouse as a Model System2011 Grant RecipientsAnirban Mitra, PhD, University of Chicago
How Do Cells Near Ovarian Cancer Cells Play a Role in the Disease?Gregory Motz, PhD, University of Pennsylvania
Stimulating Immune Cells to Fight Ovarian CancerRuth Perets, MD, PhD, Dana Farber Cancer Institute
Trying to Identify the Cell Responsible for Ovarian CancerSharmistha Sarkar, PhD, MD Anderson Cancer Center
Finding a Marker to Detect Early Stage Ovarian CancerSherry Wu, PhD, MD Anderson Cancer Center
Novel Approach to Destroy the Blood Supply that Feeds Ovarian Cancer TumorsTsz-Lun Yeung, PhD, MD Anderson Cancer Center
Understanding How Ovarian Cancer Spreads2008 Grant RecipientsWeiwei Shan, PhD, MD Anderson Cancer Center
Cellular Microenvironment Role in Ovarian Cancer DevelopmentTakayo Ota, MD, PhD, Mayo Clinic Rochester
Characterizing the Genetic Alterations of Aggressive Ovarian CancerXiaoping He, MD, PhD, Mayo Clinic Rochester
Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian CancerThuy-Vy Do, PhD, Fox Chase Cancer Center
Understanding How Ovarian Cancer SpreadsLejla Delic, MD, Cedars-Sinai Medical Center
A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors2007 Grant RecipientsHong Zhang, PhD, Fox Chase Cancer Center
Novel Animal Model to Test Drugs Against Ovarian CancerMelissa Merritt, PhD, Brigham and Women’s Hospital
How Might Different Tissues in the Ovary Act on Each Other to Induce CancerMitchell Cheung, PhD, Fox Chase Cancer Center
Testing New Therapeutic Agents to Treat Ovarian CancerKuang-Hung Cheng, PhD, Brigham and Women’s Hospital
Animal Model to Study Ovarian Cancer Stem Cells2006 Grant RecipientsRamandeep Rattan, PhD, Mayo Clinic
Gene May Be an Early Marker for Ovarian CancerAndres Matoso, MD, Cornell University
An Animal Model to Study Major Genetic Alterations in Ovarian CancerAliza Leiser, MD, Yale University
Clinical Implications of the TLR-4MYD88 Pathway in EOCAudrey Gagnon, PhD, Brigham and Women’s Hospital
New Analytical Tool for Ovarian Cancer DetectionAdam Clauss, PhD, Dana Farber Cancer Institute
Does Ovarian Cancer Originate in the Fallopian Tube?Maria Barbolina, PhD, University of Illinois – Chicago
Epigenetic Regulation of Metastasis-Associated Gene Expression in EOCTsukasa Baba, Duke University
Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer2005 Grant RecipientsDeyin Xing, MD, PhD, Massachusetts General Hospital
Models to Study Hereditary Ovarian CancerJason Wilken, PhD, Yale University
Making an Antibody Treatment for Breast Cancer Work for Ovarian CancerRitu Salani, MD, Johns Hopkins University School of Medicine
DNA Fragments Might be a Way to Screen for Ovarian CancerJoseph Kwong, PhD, Brigham and Women’s Hospital
Could Inflammation of Ovarian Cells be the Cause of Ovarian Cancer?Amy BonDurant, MD, Duke University
Chemical Changes on DNA May Be a Way to Screen for Ovarian Cancer and its RecurrenceDonna Badgewell, PhD, MD Anderson Cancer Center
Developing a Screening Test for Ovarian Cancer2004 Grant RecipientsXiaoyan Ni, PhD, Brigham and Women’s Hospital
Biomarkers for Ovarian CancerBrian Barnett, MD, Tulane University Health Sciences Center
Depleting Regulatory T Cells to Treat Ovarian Cancer2003 Grant RecipientsMonique Spillman, MD, PhD, Duke University Medical Center
Role of MAP2K4 Suppressing Metastasis of Serous Ovarian CancersNaomi Hunder, MD, Fred Hutchinson Cancer Research Center
Evaluation of Mesothelin as a Taret Antigen in Ovarian CancerKuan-Chun Huang, PhD, Brigham and Women’s Hospital
A Possible New Marker for Drug Resistance of Ovarian CancerJeremy Chien, PhD, Mayo Clinic
How Cell Shape Changes Lead to Metastasis in Ovarian Cancer
Health Equity Research Grant
OCRA’s first-ever Health Equity Research Grant (HEG) was launched in 2024 and sponsored by GSK. It is intended to overcome barriers to care faced by marginalized communities and is geared to all investigators with projects focusing on ovarian cancer and/or related gynecologic cancers research that have a health equity focus. Support of $100,000 annually for two years will be awarded to the institution where the recipient will conduct the research.
Related Topics
OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
OCRA-Funded Research Expands Impact of DNA and RNA Data
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued